The Sanger sequencing method has been considered the gold standard DNA sequencing technique for the last 30 years; however, it is now being challenged by next-generation sequencing (NGS). The aim of this study was to assess the costs entailed with the Sanger DNA sequencing method for somatic genetics.
Results

Study limitations and conclusions
displays the mean costs of the Sanger sequencing. The mean total cost was €1,891, mean cost per patient €108, and mean cost per exon €18. The marginal costs of the patients and exons are presented in figure 1. Each additional patient increases the predicted cost by €112 and each additional exon by €12.
 Personnel and consumables are the highest costs drivers
• On average, expenditures on personnel amounted to €756 (around 52% of the total cost). This was particularly high because of the higher workload for the technicians and higher wages for the biologists conducting the bioinformatic analyses.
• Costs for consumables and reagents were on average €655, roughly 43% of the total cost. These were mainly driven by single, expensive reagents.
• Equipment cost and its maintenance contributed 5% to the total cost.
 Bioinformatic analysis and DNA extraction were the most expensive stages
• The bioinformatic analysis and DNA extraction were the most expensive stages. These two stages represented 28% and 26% of the total cost, respectively.
• The costs of the stages related to PCR amounted to €134 and €187, about 21% of the total cost.
• The sequence reaction, sequence purification, and sequence migration had an average cost of €113, €109, and €153, respectively; they contributed to about a quarter of the total cost.
 The costs of most of the stages of Sanger sequencing were determined by roughly one input factor
• The tornado diagrams* are shown in figure 2 and present the cost variation induced by a 10% unit price change in the highest cost item of a respective stage. The highest cost items were the technician for DNA extraction and PCR, biologist for bioinformatic analysis, and reagents (PCR clean-up kit, big dye terminator, and polymer for the PCR purification, sequence reaction, and sequence migration stages, respectively).
• Because of the high costs of observing and evaluating Sanger sequencing sessions, our sample size was limited to five observations. Therefore, we could not perform a probabilistic sensitivity analysis. Our findings demonstrate the moderate costs of Sanger sequencing. The costs were a linear function of the number of patients and exons especially influenced by the high costs for personnel and consumable. The first and last stages were the most expensive. These results will be used for further economic analyses to compare Sanger sequencing with other DNA sequencing methods, for instance NGS.
• This study was supported by the National Cancer Institute (INCa).
• Unit prices and costs were provided by the accounting departments from the participating centers (expressed in year 2014 Euro, inclusive of tax).
The mean total cost among the five observations was calculated. The costs were correlated with the number of patient samples and exons. Therefore, the mean cost per exon and mean cost per patient among the five observations were calculated. The marginal costs per exon and per patient were estimated. The mean cost per cost driver, i.e. personnel, consumables and reagents, equipment, maintenance, and structure, were calculated. The mean cost per stage, i.e. DNA extraction, PCR, purification, etc., were computed to detect any heterogeneous effects among the stages.
 Statistical analysis
• The uncertainty surrounding the costs was assessed using a deterministic sensitivity analysis. Due to the variety of different resources used in the different stages, oneway analyses (Tornado diagrams) for each stage of the sequencing process were conducted.
• All statistical analyses were performed using STATA® software (version 14.0).
 Study design
• Five sequencing sessions were investigated in four French cancer centers from February 2015 to May 2015: Léon Bérard Cancer Centre (CLB), Lyon; Edouard Herriot Hospital (HEH), Lyon; Gustave Roussy (GR), Paris; University hospital (HHL), Pessac.
• Seven stages of Sanger sequencing were identified: deoxyribonucleic acid (DNA) extraction, polymerase chain reaction (PCR), purification, sequence reaction, sequence purification, sequence migration, and bioinformatics analysis.
 Cost assessment
• Cost calculations were based strictly on a micro-costing approach according to the hospitals' perspective.
• All of the resources used -from the reception of the sample to the bioinformatic analysis-were taken into consideration. Direct, management (25% surcharge on personnel cost), and structure (27% surcharge on total cost) costs were taken into account.
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